Exelixis Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Exelixis Inc (EXEL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$23.03 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-10
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2026 was -$23.03M, a 3563.01% decline from fiscal 2025.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $665.00K, a 37.62% decline from fiscal 2023.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $1.07M.
- Exelixis Inc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was -$2.86M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2026-01-02 | -$23.03M 10-K · filed 2026-02-10 |
| 2025-01-03 | $665.00K 10-K · filed 2026-02-10 |
| 2023-12-29 | $1.07M 10-K · filed 2026-02-10 |
| 2022-12-30 | -$2.86M 10-K · filed 2025-02-11 |
| 2021-12-31 | -$11.83M 10-K · filed 2024-02-06 |
| 2021-01-01 | -$20.40M 10-K · filed 2023-02-07 |
| 2020-01-03 | -$9.18M 10-K · filed 2022-02-18 |
| 2018-12-28 | -$6.00M 10-K · filed 2021-02-11 |
| 2017-12-29 | -$20.55M 10-K · filed 2020-02-25 |
| 2016-12-31 | $3.15M 10-K · filed 2017-02-27 |
| 2016-12-30 | $3.15M 10-K · filed 2019-02-22 |
| 2016-01-01 | $195.00K 10-K · filed 2018-02-26 |
| 2015-12-31 | $195.00K 10-K · filed 2017-02-27 |
| 2014-12-31 | $255.00K 10-K · filed 2017-02-27 |
| 2013-12-31 | $393.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $504.00K 10-K · filed 2015-03-02 |
| 2011-12-31 | $627.00K 10-K · filed 2014-02-20 |
| 2010-12-31 | $1.71M 10-K · filed 2013-02-21 |
| 2009-12-31 | $2.64M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |